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Market research vs. marketing
Market research is invariably confused with marketing – but, in fact, the two disciplines are very diffe-
rent. Put in its simplest terms, marketing is about promotion whilst market research is about under-
standing. Accordingly, data collected for market research purposes are used in a completely different 
way to that gathered for marketing, with research practices heavily regulated to ensure high ethical 
standards.
Let’s begin with a definition of what, exactly, market research is. According to the ICC/ESOMAR In-
ternational Code 2007 (a definition also adopted by the European Pharmaceutical Market Research 
Association), it is: «the systematic gathering and interpretation of information about individuals or or-
ganisations using the statistical and analytical methods and techniques of the applied social sciences to 
gain insight or support decision-making. The identity of respondents will not be revealed to the user of 
the information without explicit consent and no sales approach will be made to them as a direct result 
of their having provided information».
In other words, market research is carried out by independent agencies, commissioned by pharma-
ceutical companies, who gather information that is consolidated into aggregated reports with no refe-
rences to individual doctors. Extensive regulations safeguard respondents’ rights and ensure privacy 
of information.
Whilst some doctors may be unclear as to how their information will be used – and feel cautious about 
participating in market research as a result – they need not fear. It will never find its way into a database 
that is subsequently used for sales and marketing. 
What’s more, market research has significant benefits for doctors and the wider industry.
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What are the benefits to doctors?
Primarily, market research helps companies to develop new drugs that actually meet the needs of 
marketplace – i.e. drugs of interest from a clinical perspective as well as a scientific one. On a more 
pragmatic level, it also makes the contact between doctors and the industry more relevant to doctors’ 
needs (after all, sales representatives will waste less of doctors’ limited time if they know what, overall, 
they are interested in). Fundamentally, it helps the industry to be more efficient overall and more focu-
sed on the things that are really needed.
There are, of course, incentives for doctors taking part in market research studies; these too are regula-
ted to make sure they’re entirely commensurate with the task involved.
How is market research regulated?
We’ve talked about regulation, but who holds this important responsibility? Certain aspects, primarily 
around data protection, are of course covered by law – but the setting of high ethical and professional 
standards is the job of the European Pharmaceutical Market Research Association (EphMRA). 
As the representative body for the healthcare market research industry, EphMRA exists to drive excel-
lence in professional standards, to champion members’ interests and to harness and cascade knowledge 
– all with a view to fulfilling its vision of empowering healthcare market researchers to become highly 
valued business partners. EphMRA’s ever-expanding membership includes practically all major phar-
maceutical companies worldwide, and a significant proportion of its market research suppliers. 
Prior to 2009, healthcare market research was governed by the Joint Code of Conduct with ESOMAR – 
but, as healthcare market researchers were increasingly discovering, there was a clear need for specific 
guidance on legal, ethical and data protection issues unique to this industry. In order to meet this de-
mand, EphMRA commissioned a dedicated in-house team, along with consultancy support, to create a 
Code of Conduct that would provide vital guidance on defining and safeguarding respondents’ rights 
and protecting data integrity when conducting primary healthcare market research in international 
markets. The subsequent introduction of the EphMRA Code of Conduct in 2009 was undoubtedly one 
of the biggest and most important initiatives of the Association’s 50-year history.
Today, the EphMRA Code covers everything from respondents’ rights to regulation of incentives to 
adverse event reporting – as well as all legal requirements. It regulates interviews with patients as well as 
doctors, and covers how we deal with sensitive subjects and patient groups. It also includes clear rules 
around product-testing, so it is not confused with clinical studies. And, having been informed by exten-
sive dialogue with market research organisations worldwide, EphMRA’s Code is very much intended for 
international use. As such, it is a comprehensive guide for today’s healthcare market researcher.
Perhaps the most important thing to say about the Code, however, is that it is a living, breathing entity. 
One that is, and always will be, regularly updated in order to keep apace with the industry. 
Although compliance with the Code is not currently compulsory (excepting those aspects of data pro-
tection required by law), EphMRA works hard to optimise its uptake and value. So far, it has established 
a Code Query Service for Members, offers Code training in multiple formats, and has established com-
petency certification for members who wish to demonstrate their knowledge and commitment.
A snapshot of the Code
But back to actual content of the Code of Conduct. To give a flavour of the type of regulations by 
which healthcare market researchers are governed, below is a snapshot of the Code’s three main areas. 
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There are many country-specific variances within these – all covered by the Code – but below are the 
common principles.
On respondents’ rights
Fundamentally, safeguarding respondents’ rights and detailing researchers’ responsibilities towards 
them is what the Code of Conduct is all about.
Specifically, the Code states that respondents’ participation in MR must be voluntary and the respon-
dent must be made aware of a number of points. These are: what exactly is involved; the confidentiality 
and anonymity of the process; the fact that the research is not in any way promotional; how the infor-
mation will be used; the need for adverse event reporting; and their right to withdraw at any time. Ad-
ditionally, re-contacting respondents on the same study is only permitted if agreed during recruitment 
or interview.
On protection of privacy & personal data
This element of the Code is in fact a legal requirement, based on a Data Protection directive from the 
European Union. The EU enforces strict controls on the processing of personal data (i.e. any informa-
tion that can identify an individual – their initials, pieces of information that can single out a specialist 
in a small study and, in Germany, even an IP address). Also, the transfer of personal data to a non-EU 
country is forbidden unless privacy protection is in place. 
So, what specific protocols exist to support us in complying with data protection law? Firstly, the man-
date to store personal data securely. Secondly, there are a number of protocols for the transfer of data 
– within the EU, between the EU and US, and even within a single multinational company. And the 
absolute rule: MR data cannot be used to build databases used for non-market research purposes, in 
particular for sales and marketing activities.
… Adverse Event (AE) reporting
The Code also covers adverse event reporting, which has become a big issue for the industry. 
Whilst there is no universal agreement on how this should operate within the context of MR, EphMRA 
advises members to establish in advance with the client (or local association) the specific AE reporting 
requirements for each study. However, EphMRA’s Code does offer recommendations on AE reporting: 
the interviewer must remind the respondent to report when an adverse event is mentioned in the 
course of an interview. Patients would then be responsible for informing their doctor, and doctors for 
informing the pharmaceutical company and/or the authorities.
… Incentives
The Code of Conduct recommends that incentives are kept to a minimum – always appropriate to the 
respondent type and commensurate with the time and task involved. What kinds of incentives are not 
allowed? In short, anything that influences opinion or behaviour, requires the respondent to spend mo-
ney (e.g. to claim a discount), is subject to use of the company’s goods or services, or is a covert means 
of collecting personal data.
What’s next for the EphMRA Code of Conduct?
Currently the Code of Conduct covers ten markets (G5 Europe, USA, Denmark, Finland, Norway and 
Sweden) with extensions to China, Japan and India underway. Russia, Turkey and Poland will follow 
shortly afterwards. Collaboration with relevant local and international associations is ongoing, and 
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training has become even more accessible due to a new free online module. There is also in the pipeline 
a potential member consultation on making the Code mandatory. 
In sum, the Code of Conduct is one of the most important EphMRA initiatives of recent times, and it 
continues to evolve. Over the last 18 months it has become established as the industry standard for our 
business. The geographical expansion to new countries, especially emerging markets, makes it set to 
become the healthcare gold standard for our business globally. Above all it gives you the reassurance 
that participation in market research studies is completely anonymous, highly regulated and ultimately 
making the pharmaceutical industry more relevant to your needs.
